Lexaria Bioscience (LEXX) EBIAT (2017 - 2026)
Lexaria Bioscience's EBIAT history spans 10 years, with the latest figure at -$1.5 million for Q1 2026.
- Quarterly results put EBIAT at -$1.5 million for Q1 2026, up 46.53% from a year ago — trailing twelve months through Feb 2026 was -$9.5 million (down 1.5% YoY), and the annual figure for FY2025 was -$11.9 million, down 105.06%.
- EBIAT for Q1 2026 was -$1.5 million at Lexaria Bioscience, up from -$1.6 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of -$649539.0 in Q1 2024 to a low of -$3.8 million in Q2 2025.
- The 5-year median for EBIAT is -$1.8 million (2022), against an average of -$1.9 million.
- The sharpest move saw EBIAT surged 49.96% in 2024, then crashed 318.29% in 2025.
- Year by year, EBIAT stood at -$1.8 million in 2022, then skyrocketed by 32.84% to -$1.2 million in 2023, then plummeted by 129.51% to -$2.7 million in 2024, then skyrocketed by 40.98% to -$1.6 million in 2025, then grew by 9.06% to -$1.5 million in 2026.
- According to Business Quant data, EBIAT over the past three periods came in at -$1.5 million, -$1.6 million, and -$2.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.